Skip to content
Business

Novo Nordisk Says Early CagriSema Responders Lost 25.4% of Body Weight in 68 Weeks

Novo Nordisk says patients who responded early to its obesity shot CagriSema lost 25.4% of their body weight in 68 weeks, but the post hoc analysis is no guide to treatment yet.

Novo Nordisk's NN1 headquarters building on Krogshøjvej in Bagsværd, Denmark
Photo: Toxophilus / Wikimedia Commons, CC BY-SA 4.0

Novo Nordisk says two in three patients on its experimental obesity shot CagriSema lost at least 5% of their body weight within eight weeks, and that this group went on to lose 25.4% on average by week 68. The figures come from a fresh look at a finished trial, not a new study, and they arrive weeks before US regulators are due to decide whether the drug can be sold there.

CagriSema at ObesityWeek 2026

  • 25.4% average weight loss at week 68 among early responders in REDEFINE 1
  • 67.8% share of CagriSema patients who counted as early responders
  • Q4 2026 when Novo expects a US decision on the drug

Novo went back to a finished trial

Novo released the analysis on Sunday 15 November at ObesityWeek 2026, a medical conference in Washington, DC. It returns to REDEFINE 1, a 68-week phase 3 trial in 3,417 adults with obesity or overweight, at least one related health problem and no type 2 diabetes.

CagriSema is a once-weekly injection that pairs semaglutide with cagrilintide, a long-acting version of the hormone amylin. According to Novo, the two molecules cut hunger and make people feel fuller, so they eat less.

This time the company sorted patients on the 2.4mg/2.4mg dose by how quickly the drug took hold. An early responder was anyone who had lost at least 5% of their body weight by week 8. Everyone else counted as a delayed responder.

Novo Nordisk: share price, chart and news

The front entrance of Novo Nordisk's US headquarters in Plainsboro, New Jersey.
The front entrance of Novo Nordisk's US headquarters in Plainsboro, New Jersey. Photo: Jonathan Schilling / Wikimedia Commons, CC BY-SA 4.0
NOVO-B in the three months to 16 November 2026. Daily closing prices from exchange data.
NOVO-B in the three months to 16 November 2026. Daily closing prices from exchange data.

Fast starters kept losing weight

Of the patients analysed, 67.8% cleared the eight-week bar, and Novo said women were more likely than men to respond early. By week 68 they had lost 25.4% of their weight on average, and almost three in four had shed a fifth or more. The slower group still lost 17.8%.

GroupPatientsLoss at week 8Loss at week 68Lost 20% or more
Early responders1,3677.8%25.4%73.3%
Delayed responders6493.4%17.8%37.2%

The figures cover only the time people were taking the drug.

"Obesity is a chronic disease, and people respond to treatment differently and over different timeframes," said Martin Holst Lange, Novo's chief scientific officer and head of research and development.

A second analysis of the same trial asked how patients felt about daily life. At week 68, 73.1% of those on CagriSema reported a meaningful improvement in physical function, such as carrying out everyday activities, against 49.1% on placebo. For psychosocial function, which covers self-esteem and comfort in social situations, the figures were 69.0% and 42.1%. Both comparisons assume every patient stayed on treatment.

The analysis comes with big caveats

Novo itself calls the early-responder figures post hoc and hypothesis-generating: the question was asked after the trial had finished, so the answer can suggest ideas for future studies but cannot prove them. Dr W. Timothy Garvey of the University of Alabama at Birmingham, an author of the analysis, was blunt.

"These values are hypothesis-generating, and they are not the basis for changing clinical decision-making," he said in the company's release.

Side effects were common. In REDEFINE 1, 79.6% of patients on CagriSema reported gastrointestinal problems, against 39.9% on placebo. Nausea affected 55% of CagriSema patients, against 12.6% on placebo, while 30.7% had constipation and 26.1% vomited. Novo said these events were mostly short-lived and mild to moderate, but 5.9% of CagriSema patients stopped treatment because of side effects, compared with 3.5% on placebo.

What the new figures do not show

  • They do not come from a new trial: they re-slice REDEFINE 1, which has already reported
  • They cannot tell a doctor in advance which patient will respond early
  • They do not change the result of the head-to-head trial against tirzepatide

CagriSema trailed tirzepatide in a direct contest

On 23 February Novo reported that REDEFINE 4, an open-label 84-week trial in 809 people, had missed its main goal: showing that CagriSema was not meaningfully worse than tirzepatide 15mg, its strongest rival. If everyone had stuck with treatment, CagriSema patients lost 23.0% of their weight against 25.5% on tirzepatide. Counting everyone, whether or not they kept going, the figures were 20.2% and 23.6%.

Novo also brought lower doses to Washington. REDEFINE 9 tested 1.7mg/1.7mg and 1.0mg/1.0mg in 309 adults, and Novo announced the results on Saturday 14 November alongside publication in The Lancet Diabetes & Endocrinology. If all patients had stayed on treatment, they lost 20.7% and 21.0% after 68 weeks, against 2.0% on placebo. Counting everyone, the losses were 19.4% and 18.6%, against 4.6%.

A US decision is due this quarter

Novo filed CagriSema 2.4mg/2.4mg with the US Food and Drug Administration in December 2025 and expects a decision in the fourth quarter of 2026. The filing rests on the REDEFINE 1 and REDEFINE 2 trials, the company said in February. The drug is not approved in the US, and Novo stresses that its safety and efficacy have not been established.

In February Novo also said REDEFINE 11, a trial designed to measure CagriSema's full weight-loss potential, should report in the first half of 2027.

Questions and answers

What did Novo Nordisk show about CagriSema at ObesityWeek 2026?

In a post hoc analysis of the REDEFINE 1 trial, 67.8% of patients on CagriSema lost at least 5% of their weight by week 8. That group lost 25.4% on average by week 68, against 17.8% for slower responders.

Is CagriSema approved in the US?

No. Novo Nordisk filed CagriSema with the FDA in December 2025 and expects a decision in the fourth quarter of 2026.

How does CagriSema compare with tirzepatide?

In the REDEFINE 4 head-to-head trial, CagriSema produced 23.0% average weight loss against 25.5% for tirzepatide over 84 weeks, if all patients stayed on treatment. It failed to show it was not meaningfully worse.

Sources

Related stories

Business

Novo Nordisk Shares Slump as Investors Shrug Off 2030 Blockbuster Targets

Novo Nordisk targeted more than five blockbusters by 2030 and over DKK 150 billion of pipeline sales in 2035, but its shares fell as much as 9 percent as investors questioned the…

Investing

Novo Nordisk Raises Its 2026 Outlook as the Wegovy Pill Takes Off

Novo Nordisk's adjusted operating profit rose 27% to DKK 31.7bn in the third quarter, helped by DKK 5.4bn of Wegovy pill sales, and it now sees 2026 growth of minus 2% to plus 2%.

Markets

Meta Soars 12.9% and AMD Hits $1 Trillion as the AI Rally Lifts the Nasdaq 3.3%

Meta rose 12.9% on the week after its Muse assistant topped Apple's app chart, and AMD passed a $1tn market value. The Nasdaq 100 gained 3.25%, while Novo Nordisk fell 10.14% and…

Markets

Novartis Sinks 13.5% on Twin Trial Failures as Brent Breaks $100 and the ECB Hikes

Novartis fell 13.54% in the week to 11 September after two late-stage trial failures, while Brent jumped 8.65% to $104.61 a barrel and the ECB raised rates for the second time this…

Business

Québecor Makes a C$31bn Cash-and-Share Bid for Telus, Which Warns of Regulatory Risk

Québecor has offered C$6.35 in cash plus 0.17 of its own shares for each Telus share, a bid worth about C$31bn. The Telus board says the price falls short and the regulatory risk…

Business

Tyson Foods Shares Jump 8.7% as Beef Outlook Outweighs a $74m Quarterly Loss

Tyson Foods posted a $74m fourth-quarter net loss and adjusted EPS of $0.61, down 47%, yet its shares closed 8.7% higher on Monday as its 2027 beef outlook pointed to far smaller…

Business

Roche Wins FDA Approval for Breast Cancer Pill Wilserdly After 62% Cut in Progression Risk

The FDA approved Roche's all-pill Wilserdly combination for ESR1-mutated advanced breast cancer after it cut the risk of progression or death by 62%. A ruling on early-stage use is…

Business

ULA Loses Its First Mission as Vulcan Rocket Fails With 40 Amazon Leo Satellites on Board

United Launch Alliance's Vulcan rocket failed about 10 minutes after lift-off on Sunday, and all 40 Amazon Leo satellites were lost. Amazon fell 3.3% on Monday as space stocks…